Theragenics, Oncura ink brachytherapy deal

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Theragenics, a medical device company serving the surgical products and prostate cancer treatment markets, has signed a loading services agreement with Oncura, a unit of GE Healthcare, to provide worldwide brachytherapy loading services to Oncura.

Under the three-year agreement, Theragenics will load and package Oncura manufactured brachytherapy seeds in prescription loaded needles, custom strands and other configurations. Oncura’s iodine-125 brachytherapy seeds are utilized primarily in the treatment of early stage prostate cancer. This agreement provides for loading services for most Oncura sales of prescription and custom-loaded brachytherapy seeds worldwide, which currently includes North America, Europe, Australia and portions of Asia.